Webinar: Denmark as a location for clinical trials in hematology
Where do you go to conduct the clinical trials that your business depends on?
For a growing number of the world’s major life science companies, the answer is Denmark. Let us provide you with an virtual introduction to the reasons why Denmark is such a great location for hematology clinical trials in this exclusive webinar.Partner webinar collaboration with Trial Nation
Webinar programme
An introduction to Trial Nation by CEO Marianne Pilgaard, describing their services towards global companies and clinical researchers wishing to conduct clinical trials in Denmark.Presentation of the hematologic clinical sites in Denmark by Dr. Abildgaard. The presentation will include statistics on prevalence and patient population with hematologic cancers. Dr. Abildgaard will also focus on Odense University Hospital, where he is in charge of research and clinical trials and his departments capabilities. He will especially focus on the newly established Elite Research Center for Cellular Immuno-therapy in Hematological Cancer (CITCO).
Presentation of the work on immunotherapy (CAR-T) and bi-specific antibodies, and hemopoietec stem cell transplantation undertaken in Denmark by Dr. Hutchings. Dr. Hutchings, who is also responsible for the Phase I unit at Copenhagen University Hospital (Rigshospitalet), will also focus the first-in-human experiences and capabilities at the site. Lastly, he will spent some time on the latest breakthrough study using bi-specific antibody treatment (glofitamab) in lymphoma patients published in Journal of Clinical Oncology.
get to know the Speakers
Dr. Niels Abildgaard
Clinical professor Niels Abildgaard is a hematologist. He is a responsible for treatment of myelomatose and Head of the Clinical Research Unit at Odense University Hospital. Professor Aabildgaard is furthermore Head of the Danish Myelomatoses Study Group and Medical Lead for Trial Nation Center for Hematology.
Dr. Martin Hutchings
Senior Consultant Martin Hutchings is a haemato-oncologist. He is responsible for treatment of malignant lymphoma and for phase I treatment of haematological malignancies at Copenhagen University Hospital (Rigshospitalet). The clinic has recruited the first patient world-wide for 6 of the 12 latest clinical trials. Dr. Hutchings is furthermore Head of service for Hodgkin lymphoma, Mantle cell lymphoma and Castleman’s disease.
facts Why conduct clinical trials in Denmark?
Get in touch Are you interested in a 1-1 meeting prior to or after the webinar or have specific questions that you would like the speakers to address?
Please contact our dedicated advisors here: